Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy

Diabetic Medicine

Volumn 22, Issue 8, 2005, Pages 999-1004

  Targher, Giovanni ^a,b   Bertolini, L ^a   Zoppini, G ^b   Zenari, L ^a   Falezza, G ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Endothelial dysfunction; Microvascular complications; Subclinical inflammation; Type 1 diabetes

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN HS CRP; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENDOTHELIUM INJURY; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; SMOKING; STATISTICAL ANALYSIS; VASCULAR DISEASE;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; VON WILLEBRAND FACTOR;

EID: 22644438381     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01562.x     Document Type: Article

References (25)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
4. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36-52.
5. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-1160.
6. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 2003; 134: 10-17.
7. Dandona P, Aljada A, Chaudhauri A, Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2422-2429.
8. Myrup B, deMaat M, Rossing P, Gram J, Kluft C, Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 1996; 81: 485-490.
9. Fasching P, Veitl M, Rohac M, Streli C, Schneider B, Waldhausel W et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocr Metab 1996; 81: 4313-4317.
10. Stehouwer CDA, Zellenrath P, Polak BCP, Baarsma GS, Nauta JJP, Donker AJM et al. Von Willebrand factor and early diabetic retinopathy: no evidence for a relationship in patients with type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion. Diabetologia 1992; 35: 555-559.
11. Limb GA, Soomro H, Janikoun S, Hollifield RD, Shilling J. Evidence for control of tumor necrosis factor-α (TNF-α) activity by TNF receptors in patients with proliferative retinopathy. Clin Exp Immunol 1999; 115: 409-414.
12. Schalkwijk CG, Poland DCW, van Dijk W, Kok A, Emeis JJ, Drager AM et al. Plasma concentration of C-reactive protein is increased in type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-357.
13. Huvers FC, De Leeuw PW, Houben AJHM, De Haan CHA, Hamulyak K, Schouten H et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999; 47: 1300-1307.
14. Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 2001; 24: 956-957.
15. Zoppini G, Targher G, Cacciatori V, Guerriero A, Muggeo M. Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients. Diabetes Care 1999; 22: 1871-1874.
16. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, Targher G. Elevated plasma levels of soluble receptors of TNF-α and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab 2001; 86: 3805-3808.
17. Saraheimo M, Teppo AM, Forsblom C, Groop PH. on behalf of the Finn-Diane Study Group. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003; 46: 1402-1407.
18. Greaves M, Malia RG, Goodfellow K, Mattock M, Stevens LK, Stephenson JM et al. Fibrinogen and von Willebrand factor in IDDM relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate. The EURODIAB IDDM complications study. Diabetologia 1997; 40: 698-705.
19. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. The EURODIAB Prospective Complications study. Diabetes Care 2003; 26:2165-2173.
20. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs; an extension of the modified Airlie House classification. ETDRS report number 10. Ophtalmology 1991; 98: 786-806.
21. Pankewycz OG, Guan JX, Benedict JF. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr Rev 1995; 16: 164-176.
22. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S. Role of vasoactive factors in the pathogenesis of early changes of diabetic retinopathy. Diabetes Metab Res Rev 2000; 16: 393-407.
23. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W et al. Blockade of receptor for advanced glycation end-products: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003; 419: 80-88.
24. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. The EURODIAB Prospective Complications study. Diabetes Care 2001; 24: 284-289.
25. Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A et al. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 2002; 25: 1432-1438.